Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

Stock Information for Shattuck Labs Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Shattuck Labs Inc.

Shattuck Labs to Participate in Upcoming December Investor Conferences
Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel
Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors
Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million
Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism
Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.